



FEP Medical Policy Manual

FEP 2.04.94 Genetic Testing for Lactase Insufficiency

Effective Policy Date: October 1, 2023

Original Policy Date: September 2013

Related Policies:

None

Genetic Testing for Lactase Insufficiency

Description

Description

Genetic testing of adults with suspected lactase insufficiency is proposed as an alternative to current diagnostic practices, which include hydrogen breath test, lactose tolerance blood test, and intestinal biopsy.

OBJECTIVE

The objective of this evidence review is to determine whether targeted testing for the *MCM6* -13910C>T variant improves the net health outcome for individuals with suspected lactase insufficiency.

POLICY STATEMENT

The use of targeted *MCM6* -13910C>T variant analysis for the prediction of lactase insufficiency is considered **investigational**.

POLICY GUIDELINES

Genetics Nomenclature Update

The Human Genome Variation Society nomenclature is used to report information on variants found in DNA and serves as an international standard in DNA diagnostics. It was implemented for genetic testing medical evidence review updates in 2017 (see Table PG1). The Society's nomenclature is recommended by the Human Variome Project, the Human Genome Organization, and by the Human Genome Variation Society itself.

The American College of Medical Genetics and Genomics and the Association for Molecular Pathology standards and guidelines for interpretation of sequence variants represent expert opinion from both organizations, in addition to the College of American Pathologists. These recommendations primarily apply to genetic tests used in clinical laboratories, including genotyping, single genes, panels, exomes, and genomes. Table PG2 shows the recommended standard terminology—"pathogenic," "likely pathogenic," "uncertain significance," "likely benign," and "benign"—to describe variants identified that cause Mendelian disorders.

Table PG1. Nomenclature to Report on Variants Found in DNA

Previous	Updated	Definition
Mutation	Disease-associated variant	Disease-associated change in the DNA sequence
	Variant	Change in the DNA sequence
	Familial variant	Disease-associated variant identified in a proband for use in subsequent targeted genetic testing in first-degree relatives

Table PG2. ACMG-AMP Standards and Guidelines for Variant Classification

Variant Classification	Definition
Pathogenic	Disease-causing change in the DNA sequence
Likely pathogenic	Likely disease-causing change in the DNA sequence
Variant of uncertain significance	Change in DNA sequence with uncertain effects on disease
Likely benign	Likely benign change in the DNA sequence
Benign	Benign change in the DNA sequence

ACMG: American College of Medical Genetics and Genomics; AMP: Association for Molecular Pathology.

Genetic Counseling

Experts recommend formal genetic counseling for individuals who are at risk for inherited disorders and who wish to undergo genetic testing. Interpreting the results of genetic tests and understanding risk factors can be difficult for some individuals ; genetic counseling helps individuals understand the impact of genetic testing, including the possible effects the test results could have on the individual or their family members. It should be noted that genetic counseling may alter the utilization of genetic testing substantially and may reduce inappropriate testing; further, genetic counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.

BENEFIT APPLICATION

Experimental or investigational procedures, treatments, drugs, or devices are not covered (See General Exclusion Section of brochure).

Screening (other than the preventive services listed in the brochure) is not covered. Please see Section 6 General exclusions.

Benefits are available for specialized diagnostic genetic testing when it is medically necessary to diagnose and/or manage a patient's existing medical condition. Benefits are not provided for genetic panels when some or all of the tests included in the panel are not covered, are experimental or investigational, or are not medically necessary.

FDA REGULATORY STATUS

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments (CLIA). Laboratories that offer laboratory-developed tests must be licensed by the CLIA for high-complexity testing. To date, the U.S. Food and Drug Administration has chosen not to require any regulatory review of this test.

RATIONALE

Summary of Evidence

For individuals with suspected lactase insufficiency who receive targeted testing for the *MCM6* -13910C>T variant, the evidence includes genotype-phenotype studies and a meta-analysis. Relevant outcomes are symptoms, morbid events, functional outcomes, health status measures, and quality of life. Studies have demonstrated a high correlation between the -13910C>T single nucleotide variant upstream of the gene encoding the enzyme lactase, and lactase insufficiency in persons of European ancestry. Studies in white populations have reported a high degree of agreement for the diagnosis of lactase insufficiency between genotyping and both hydrogen breath test and lactose tolerance blood test. However, there is no current treatment for lactase insufficiency, and management involves dietary restriction and palliation of lactose intolerance symptoms. Therefore, an empirical diagnosis of lactose intolerance in the absence of confirmation by hydrogen breath test, lactose tolerance blood test, or genotyping, followed by treatment with dietary restriction of lactose, is suitable. Currently, the evidence does not support the conclusion that assessment of the genetic etiology of lactose intolerance would affect clinical management or improve clinical outcomes. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

SUPPLEMENTAL INFORMATION

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in "Supplemental Information" if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

No guidelines or statements were identified.

U.S. Preventive Services Task Force Recommendations

Not applicable.

Medicare National Coverage

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

REFERENCES

- Suchy FJ, Brannon PM, Carpenter TO, et al. National Institutes of Health Consensus Development Conference: lactose intolerance and health. *Ann Intern Med.* Jun 15 2010; 152(12): 792-6. PMID 20404261
- Matthews SB, Waud JP, Roberts AG, et al. Systemic lactose intolerance: a new perspective on an old problem. *Postgrad Med J.* Mar 2005; 81(953): 167-73. PMID 15749792
- Shaukat A, Levitt MD, Taylor BC, et al. Systematic review: effective management strategies for lactose intolerance. *Ann Intern Med.* Jun 15 2010; 152(12): 797-803. PMID 20404262
- Sahi T. Genetics and epidemiology of adult-type hypolactasia. *Scand J Gastroenterol Suppl.* 1994; 202: 7-20. PMID 8042019
- Wilt TJ, Shaukat A, Shamlivan T, et al. Lactose intolerance and health. *Evid Rep Technol Assess (Full Rep).* Feb 2010; (192): 1-410. PMID 20629478
- Misselwitz B, Pohl D, Frhauf H, et al. Lactose malabsorption and intolerance: pathogenesis, diagnosis and treatment. *United European Gastroenterol J.* Jun 2013; 1(3): 151-9. PMID 24917953
- Jellema P, Schellevis FG, van der Windt DA, et al. Lactose malabsorption and intolerance: a systematic review on the diagnostic value of gastrointestinal symptoms and self-reported milk intolerance. *QJM.* Aug 2010; 103(8): 555-72. PMID 20522486
- Haberborn BC, Ermens AA, Koeken A, et al. Improving diagnosis of adult-type hypolactasia in patients with abdominal complaints. *Clin Chem Lab Med.* Sep 21 2011; 50(1): 119-23. PMID 21936609
- Hgenauer C, Hammer HF, Mellitzer K, et al. Evaluation of a new DNA test compared with the lactose hydrogen breath test for the diagnosis of lactase non-persistence. *Eur J Gastroenterol Hepatol.* Mar 2005; 17(3): 371-6. PMID 15716664
- Enattah NS, Sahi T, Savilahti E, et al. Identification of a variant associated with adult-type hypolactasia. *Nat Genet.* Feb 2002; 30(2): 233-7. PMID 11788828
- Raz M, Sharon Y, Yerushalmi B, et al. Frequency of LCT-13910C/T and LCT-22018G/A single nucleotide polymorphisms associated with adult-type hypolactasia/lactase persistence among Israelis of different ethnic groups. *Gene.* Apr 25 2013; 519(1): 67-70. PMID 23415628
- Enko D, Rezanka E, Stolba R, et al. Lactose malabsorption testing in daily clinical practice: a critical retrospective analysis and comparison of the hydrogen/methane breath test and genetic test (c/t-13910 polymorphism) results. *Gastroenterol Res Pract.* 2014; 2014: 464382. PMID 24829570
- Di Stefano M, Terulla V, Tana P, et al. Genetic test for lactase non-persistence and hydrogen breath test: is genotype better than phenotype to diagnose lactose malabsorption?. *Dig Liver Dis.* Jul 2009; 41(7): 474-9. PMID 19010095
- Eadala P, Matthews SB, Waud JP, et al. Association of lactose sensitivity with inflammatory bowel disease--demonstrated by analysis of genetic polymorphism, breath gases and symptoms. *Aliment Pharmacol Ther.* Oct 2011; 34(7): 735-46. PMID 21815901
- Mendoza Torres E, Varela Prieto LL, Villarreal Camacho JL, et al. Diagnosis of adult-type hypolactasia/lactase persistence: genotyping of single nucleotide polymorphism (SNP C/T-13910) is not consistent with breath test in Colombian Caribbean population. *Arq Gastroenterol.* 2012; 49(1): 5-8. PMID 22481679
- Santonocito C, Scapatucci M, Guarino D, et al. Lactose intolerance genetic testing: is it useful as routine screening? Results on 1426 south-central Italy patients. *Clin Chim Acta.* Jan 15 2015; 439: 14-7. PMID 25281930
- Gugatschka M, Dobnig H, Fahrleitner-Pammer A, et al. Molecularly-defined lactose malabsorption, milk consumption and anthropometric differences in adult males. *QJM.* Dec 2005; 98(12): 857-63. PMID 16299058
- Bning C, Genschel J, Jurga J, et al. Introducing genetic testing for adult-type hypolactasia. *Digestion.* 2005; 71(4): 245-50. PMID 16024930
- Bulhes AC, Goldani HA, Oliveira FS, et al. Correlation between lactose absorption and the C/T-13910 and G/A-22018 mutations of the lactase-phlorizin hydrolase (LCT) gene in adult-type hypolactasia. *Braz J Med Biol Res.* Nov 2007; 40(11): 1441-6. PMID 17934640
- Schirru E, Corona V, Usai-Satta P, et al. Genetic testing improves the diagnosis of adult type hypolactasia in the Mediterranean population of Sardinia. *Eur J Clin Nutr.* Oct 2007; 61(10): 1220-5. PMID 17311063
- Bernardes-Silva CF, Pereira AC, de Ftima Alves da Mota G, et al. Lactase persistence/non-persistence variants, C/T_13910 and G/A_22018, as a diagnostic tool for lactose intolerance in IBS patients. *Clin Chim Acta.* 2007; 386(1-2): 7-11. PMID 17706627
- Szilagyi A, Malolepszy P, Hamard E, et al. Comparison of a real-time polymerase chain reaction assay for lactase genetic polymorphism with standard indirect tests for lactose maldigestion. *Clin Gastroenterol Hepatol.* Feb 2007; 5(2): 192-6. PMID 16876487
- Kerber M, Oberkanins C, Kriegshuser G, et al. Hydrogen breath testing versus LCT genotyping for the diagnosis of lactose intolerance: a matter of age?. *Clin Chim Acta.* Aug 2007; 383(1-2): 91-6. PMID 17574225
- Mattar R, Monteiro Mdo S, Villares CA, et al. Single nucleotide polymorphism C/T(-13910), located upstream of the lactase gene, associated with adult-type hypolactasia: validation for clinical practice. *Clin Biochem.* May 2008; 41(7-8): 628-30. PMID 18237552
- Krawczyk M, Wolska M, Schwartz S, et al. Concordance of genetic and breath tests for lactose intolerance in a tertiary referral centre. *J Gastrointest Liver Dis.* Jun 2008; 17(2): 135-9. PMID 18568133
- Mottes M, Belpinati F, Milani M, et al. Genetic testing for adult-type hypolactasia in Italian families. *Clin Chem Lab Med.* 2008; 46(7): 980-4. PMID 18605960
- Waud JP, Matthews SB, Campbell AK. Measurement of breath hydrogen and methane, together with lactase genotype, defines the current best practice for investigation of lactose sensitivity. *Ann Clin Biochem.* Jan 2008; 45(Pt 1): 50-8. PMID 18275674
- Nagy D, Bogcsi-Szab E, Vrkonyi A, et al. Prevalence of adult-type hypolactasia as diagnosed with genetic and lactose hydrogen breath tests in Hungarians. *Eur J Clin Nutr.* Jul 2009; 63(7): 909-12. PMID 19156157

29. Szilagyi A, Shrier I, Chong G, et al. Lack of effect of lactose digestion status on baseline fecal microflora. *Can J Gastroenterol*. Nov 2009; 23(11): 753-9. PMID 19893771
30. Babu J, Kumar S, Babu P, et al. Frequency of lactose malabsorption among healthy southern and northern Indian populations by genetic analysis and lactose hydrogen breath and tolerance tests. *Am J Clin Nutr*. Jan 2010; 91(1): 140-6. PMID 19889824
31. Pohl D, Savarino E, Hersberger M, et al. Excellent agreement between genetic and hydrogen breath tests for lactase deficiency and the role of extended symptom assessment. *Br J Nutr*. Sep 2010; 104(6): 900-7. PMID 20398434
32. Morales E, Azocar L, Maul X, et al. The European lactase persistence genotype determines the lactase persistence state and correlates with gastrointestinal symptoms in the Hispanic and Amerindian Chilean population: a case-control and population-based study. *BMJ Open*. Jul 29 2011; 1(1): e000125. PMID 22021768
33. Nilsson TK, Johansson CA. A novel method for diagnosis of adult hypolactasia by genotyping of the -13910 C/T polymorphism with Pyrosequencing technology. *Scand J Gastroenterol*. Mar 2004; 39(3): 287-90. PMID 15074401
34. Ridefelt P, Hkansson LD. Lactose intolerance: lactose tolerance test versus genotyping. *Scand J Gastroenterol*. Jul 2005; 40(7): 822-6. PMID 16109658
35. Rasinper H, Savilahti E, Enattah NS, et al. A genetic test which can be used to diagnose adult-type hypolactasia in children. *Gut*. Nov 2004; 53(11): 1571-6. PMID 15479673
36. Kuchay RA, Thapa BR, Mahmood A, et al. Effect of C/T -13910 cis-acting regulatory variant on expression and activity of lactase in Indian children and its implication for early genetic screening of adult-type hypolactasia. *Clin Chim Acta*. Oct 09 2011; 412(21-22): 1924-30. PMID 21763294
37. Mattar R, Basile-Filho A, Kemp R, et al. Comparison of Quick Lactose Intolerance Test in duodenal biopsies of dyspeptic patients with single nucleotide polymorphism LCT-13910C T associated with primary hypolactasia/lactase-persistence. *Acta Cir Bras*. 2013; 28 Suppl 1: 77-82. PMID 23381829
38. Marton A, Xue X, Szilagyi A. Meta-analysis: the diagnostic accuracy of lactose breath hydrogen or lactose tolerance tests for predicting the North European lactase polymorphism C/T-13910. *Aliment Pharmacol Ther*. Feb 2012; 35(4): 429-40. PMID 22211845
39. Arroyo MA, Lopes A, Piatto V, et al. Perspectives for early genetic screening of lactose intolerance: - 13910C/T polymorphism tracking in the MCM6 gene. *Open Biol J*. 2010;3:66-71. <https://benthamopen.com/contents/pdf/TOBIOJ/TOBIOJ-3-66.pdf>. Accessed March 13, 2023.

POLICY HISTORY - THIS POLICY WAS APPROVED BY THE FEP® PHARMACY AND MEDICAL POLICY COMMITTEE ACCORDING TO THE HISTORY BELOW:

Date	Action	Description
September 2013	New policy	
September 2014	Replace policy	Policy updated with literature search adding references 11 and 35. No changes to the policy statement
September 2015	Replace policy	Policy updated with literature review through March 10, 2015; references 12-13 and 17 added. Policy statements unchanged.
December 2017	Replace policy	Policy updated with literature review through July 20, 2017; no references added; note 1 updated. Policy statement unchanged.
September 2018	Replace policy	Policy updated with literature review through March 6, 2018; no references added. Minor edit to the Policy section; statement otherwise unchanged.
September 2019	Replace policy	Policy updated with literature review through March 4, 2019; no references added. Policy statement unchanged.
September 2020	Replace policy	Policy updated with literature review through March 9, 2020; no references added. Policy statement unchanged.
September 2021	Replace policy	Policy updated with literature review through February 11, 2021; no references added. Policy statement unchanged.
September 2022	Replace policy	Policy updated with literature review through February 14, 2022; no references added. Policy statement unchanged.
September 2023	Replace policy	Policy updated with literature review through February 13, 2023; no references added. Policy statement unchanged.

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.